Israel Akinrinsola

Israel Akinrinsola is a managing director in Evercore’s healthcare strategic advisory practice. Since joining in 2018, he has advised clients across pharmaceuticals, biotechnology, pharmaceutical services and medtech.

Mr. Akinrinsola has advised on M&A, strategic collaborations and financing transactions. Select engagements include advising Novo Nordisk on the acquisition of fill-finish sites from Novo Holdings; SIFI on its sale to Faes Farma; Autolus on its CAR-T collaboration with BioNTech; Advanced Medical Solutions on the acquisition of Peters Surgical; SERB on the acquisition of U.S. rights to bentracimab from SFJ; Sanofi on the acquisition of Principia Biopharma; Nestlé Skin Health on its sale to EQT; and Blue Earth Diagnostics on its sale to Bracco. He has also supported European IPOs on NASDAQ.

Previously, Mr. Akinrinsola was an equity research analyst covering European pharmaceuticals at Barclays and trained as a chartered accountant at EY.

Mr. Akinrinsola holds a B.Sc. in economics from Royal Holloway, University of London, and an M.Sc. in investment management from Bayes Business School.